In short
Nacystelyn (NAL), a mucolytic drug, is currently being studied in clinical trials for its potential benefits in treating Obstructive Sleep Apnea (OSA). This article explores the ongoing research on NAL's effectiveness, safety, and impact on various sleep-related parameters in patients with OSA. The trials aim to assess whether NAL, administered through a dry-powder inhaler, can improve sleep quality and reduce the severity of OSA symptoms.
At a glance
- Drug Name
- Nacystelyn (NAL)
- Administration Method
- Dry-Powder Inhaler (AXAHALER)
- Condition Studied
- Obstructive Sleep Apnea (OSA)
- Primary Objective
- Assess NAL's benefit in OSA treatment
- Primary Endpoint
- Change in Apnea-Hypopnea Index (AHI) after 6 weeks
- Key Inclusion Criteria
- Adults with OSA, AHI 15-30/h, naïve to CPAP or untreated for 2+ months
- Treatment Duration
- 6 weeks
- Secondary Measurements
- Oxygen saturation, snoring patterns, sleepiness scores, sleep quality indicators
- Safety Assessment
- Adverse events, vital signs, physical examination
What is NACYSTELYN?
NACYSTELYN, also known as NAL or L-LYSINE-N-ACETYL-L-CYSTEINATE, is a medication currently being studied for its potential benefits in treating Obstructive Sleep Apnea (OSA). It belongs to a class of drugs called mucolytics, which are typically used to help break down mucus in the airways. However, in this study, researchers are exploring its potential as an antioxidant to help with sleep apnea.
Medical Condition: Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA) is a sleep disorder where a person's breathing is repeatedly interrupted during sleep. These interruptions occur when the throat muscles intermittently relax and block the airway during sleep. This can lead to poor sleep quality, daytime sleepiness, and other health problems if left untreated.
How NACYSTELYN Works
While the exact mechanism of how NACYSTELYN might help with OSA is not fully explained in the study details, researchers are investigating its potential as an antioxidant. Antioxidants are substances that can protect cells from damage caused by free radicals. In the context of OSA, it's believed that the repeated episodes of low oxygen (known as oxidative stress) during sleep might cause inflammation and damage to tissues. By using an antioxidant like NACYSTELYN, researchers hope to reduce this oxidative stress and potentially improve OSA symptoms.
How NACYSTELYN is Administered
NACYSTELYN is being tested in two forms:
- As a capsule (10 mg)
- As an inhalation powder in a hard capsule (20 mg)
Both forms are administered using a device called an AXAHALER, which is a Monodose Dry Powder Inhaler. This is a Class 1 device designed for oral inhalation only, which delivers the medication when you breathe in. The maximum daily dose being tested is 40 mg for the capsule form and 80 mg for the inhalation powder form.
Who Can Participate in the NACYSTELYN Study?
The study is looking for adult participants with specific characteristics. Some key inclusion criteria are:
- Adults with obstructive sleep apnea
- An Apnea-Hypopnea Index (AHI) between 15 and 30 per hour. (AHI is a measure of sleep apnea severity, indicating the number of breathing interruptions per hour of sleep)
- Participants who are new to CPAP (Continuous Positive Airway Pressure, a common treatment for OSA) or haven't used it for at least two months
- An Oxygen Desaturation Index of 10 or more (This measures how often your blood oxygen level drops during sleep)
- A Body Mass Index (BMI) between 18 and 35 kg/m2
There are also several exclusion criteria, such as recent upper respiratory infections, use of certain medications, and other health conditions that might interfere with the study results.
Study Objectives and Measurements
The main goal of this study is to see if NACYSTELYN can help improve OSA symptoms. Researchers will measure this primarily by looking at the change in the Apnea-Hypopnea Index (AHI) after 6 weeks of treatment.
They will also look at many other factors, including:
- Changes in the number and duration of apnea (breathing stops) and hypopnea (shallow breathing) episodes
- Oxygen levels during sleep
- Snoring patterns
- Daytime sleepiness
- Fatigue levels
- Changes in oxidative stress and inflammation markers in the body
Potential Benefits of NACYSTELYN
If successful, NACYSTELYN could offer a new treatment option for people with OSA. Potential benefits might include:
- Reduction in the number and severity of breathing interruptions during sleep
- Improved oxygen levels during sleep
- Reduced daytime sleepiness and fatigue
- Decreased oxidative stress and inflammation in the body
However, it's important to note that these potential benefits are still being studied and are not guaranteed.
Safety Considerations
As with any medical study, safety is a key concern. The researchers will be monitoring for any side effects or adverse reactions throughout the study. Some people should not participate in this study, including those with:
- Hypersensitivity to acetylcysteine (the active ingredient in NACYSTELYN) or similar substances
- Significant unstable heart disease
- COPD (Chronic Obstructive Pulmonary Disease) or asthma
- Pregnancy or nursing
It's crucial to discuss with your doctor before considering participation in any clinical trial or starting any new treatment for OSA.